Cencora (NYSE:COR) Updates FY 2026 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 17.700-17.900 for the period, compared to the consensus EPS estimate of 17.760. The company issued revenue guidance of -.

Cencora Stock Performance

NYSE COR opened at $284.94 on Thursday. Cencora has a 1 year low of $244.82 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market capitalization of $55.44 billion, a PE ratio of 21.85, a P/E/G ratio of 1.52 and a beta of 0.59. The company has a fifty day moving average of $282.09 and a two-hundred day moving average of $322.80.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same period in the previous year, the business posted $4.42 earnings per share. The firm’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, analysts expect that Cencora will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Cencora declared that its board has authorized a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have issued reports on COR. Robert W. Baird reduced their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Evercore set a $360.00 target price on shares of Cencora in a research note on Wednesday, April 8th. Bank of America increased their price target on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Barclays decreased their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Large investors have recently modified their holdings of the stock. State Street Corp lifted its position in Cencora by 1.3% during the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after acquiring an additional 115,191 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Cencora by 80.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,661,769 shares of the company’s stock valued at $1,574,513,000 after purchasing an additional 2,085,473 shares during the period. Wellington Management Group LLP lifted its position in shares of Cencora by 14.2% during the fourth quarter. Wellington Management Group LLP now owns 4,535,992 shares of the company’s stock worth $1,532,031,000 after purchasing an additional 564,871 shares in the last quarter. Boston Partners boosted its stake in shares of Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Cencora by 5.9% in the third quarter. Northern Trust Corp now owns 2,272,464 shares of the company’s stock valued at $710,213,000 after purchasing an additional 126,929 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.